What are ADC's

Our services

ADC Review
is made possible by:


Study Title
A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas (NCT01994850)

Trial Description
This is a Phase I/II multicenter single arm non-randomized open label study of the investigational drug, brentuximab vedotin, given in combination with routine chemotherapy (rituximab, cyclophosphamide, doxorubicin and prednisone) every 3 weeks for a total of 6 cycles.

This trial is sponsored by Abramson Cancer Center of the University of Pennsylvania. [1]

Study Data

  • Condition:
    • CD30 Positive Primary Mediastinal Large B-cell Lymphom
    • CD30 Positive Diffuse Large B-cell Lymphoma
    • CD30 Positive Grey Zone Lymphoma
  • Interventions:
  • Phase: I & II
  • Estimated Enrollment: 32
  • Start: November 2013
  • Estimated Completion: November 2018
  • Last verified: January 2015

Study Schematic


Click here to Return to Drug map

Last Editorial review: July 16, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar